Well characterised animal models that can accurately predict efficacy are critical to the
development of an improved TB vaccine. The use of high dose challenge for measurement
of efficacy in Non-human primate models brings the risk that vaccines with the potential to be
efficacious against natural challenge could appear ineffective and thus disregarded.
Therefore, there is a need to develop a challenge regimen that is more relevant to natural
human infection. This study has established that ultra-low dose infection of macaques via …